Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21710432 | 0.87 | RORC (0.43) | RORCOPRL1 | |
| SCHEMBL21710544 | 0.82 | RORC (0.43) | RORCOPRL1 | |
| Hydrochloric Acid SCHEMBL20487414 | 0.81 | RORC (0.42) | RORCOPRL1 | |
| SCHEMBL18579656 | 0.81 | RORC (0.40) | RORC | |
| SCHEMBL1807735 | 0.80 | OPRL1 (0.53) | OPRL1 | |
| SCHEMBL1805146 | 0.80 | OPRL1 (0.53) | RORCOPRL1 | |
| SCHEMBL21710561 | 0.77 | RORC (0.69) | RORCOPRL1 | |
| SCHEMBL1807709 | 0.73 | OPRL1 (0.53) | RORCOPRL1 | |
| SCHEMBL26066372 | 0.71 | USP2 (0.39) | OPRL1 | |
| SCHEMBL23192562 | 0.70 | USP2 (0.39) | OPRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11008336-B2 | Compounds useful for inhibiting RORγt | ELI LILLY AND COMPANY (US) | 2021-05-18 | — | — | US | disclosed |
| EP-3589638-B1 | COMPOUNDS USEFUL FOR INHIBITING ROR-GAMMA-T | LILLY CO ELI (US) | 2021-04-07 | — | — | EP | disclosed |
| US-20200048279-A1 | COMPOUNDS USEFUL FOR INHIBITING ROR-GAMMA-T | ELI LILLY AND COMPANY | 2020-02-13 | — | — | US | disclosed |
| WO-2018160550-A1 | COMPOUNDS USEFUL FOR INHIBITING ROR-GAMMA-T | ELI LILLY AND COMPANY (US) | 2018-09-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11008336-B2 | Compounds useful for inhibiting RORγt | RORB, RORC, RORA | RORC 2/4885OPRL1 1290/4885 |
| US-20200048279-A1 | COMPOUNDS USEFUL FOR INHIBITING ROR-GAMMA-T | RORC, RORB, RORA | RORC 1/4885OPRL1 2178/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.